Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ. Weiß, K. Dragnev, J.T. Beck et al.|Annals of Oncology|2019Cited by 173
Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)Christopher A. Yasenchak, J.T. Beck, Rodolfo Bordoni et al.|Blood|2022Cited by 2